Theratechnologies (TSE:TH)‘s stock had its “sector perform” rating reiterated by equities researchers at Royal Bank of Canada in a note issued to investors on Tuesday. They presently have a C$11.00 target price on the stock. Royal Bank of Canada’s price target would suggest a potential upside of 10.78% from the company’s current price.

A number of other research analysts also recently issued reports on TH. Canaccord Genuity boosted their price target on Theratechnologies from C$13.00 to C$14.50 in a report on Friday, July 6th. National Bank Financial restated an “outperform” rating and set a C$14.25 price target on shares of Theratechnologies in a report on Wednesday, June 20th.

TH opened at C$9.93 on Tuesday. Theratechnologies has a 12 month low of C$4.96 and a 12 month high of C$14.75.

Theratechnologies (TSE:TH) last released its quarterly earnings data on Thursday, July 5th. The company reported C($0.03) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of C($0.03). The firm had revenue of C$12.33 million for the quarter, compared to the consensus estimate of C$13.40 million. Theratechnologies had a negative return on equity of 38.09% and a negative net margin of 33.47%.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.

Featured Article: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.